Has Pratibha Desai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,057,651 in general payments to Pratibha Desai, MD across 1,369 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pratibha Desai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pratibha Desai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pratibha Desai, MD

Hematology & Oncology · Saint Petersburg, FLNPI 1861488454

Payments from drug & device makers

$2,057,651in general payments, 2019–2025

Across 1,369 payments — averaging $1503.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$1M
Regeneron$420K
Kyowa Kirin, Inc.$162K
Servier Bioinnovation$137K
Institut DE Recherches Internationales Servier$68K
Mirati Therapeutics, Inc.$61K
plus $203K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	48	$1,005,357
Regeneron	33	$419,519
Kyowa Kirin, Inc.	204	$162,011
Servier Bioinnovation	13	$137,229
Institut DE Recherches Internationales Servier	4	$68,324
Mirati Therapeutics, Inc.	8	$60,676
Kyowa Kirin Pharmaceutical Development, Inc	21	$34,422
Octapharma USA, Inc.	7	$30,496
Sanofi US Services Inc.	23	$28,046
Chiesi USA, Inc.	1	$25,000
UCB SA	13	$18,280
Janssen Research & Development, LLC	3	$12,500
Morphosys AG	3	$12,198
Seagen Inc.	33	$10,301
United Therapeutics Corporation	2	$8,277
Pharmacosmos Therapeutics Inc.	12	$2,539
AstraZeneca(2 entities)	53	$2,017
Puma Biotechnology, Inc.	11	$1,981
Novartis	108	$1,880
Johnson & Johnson(2 entities)	98	$1,396
Daiichi Sankyo Inc.	48	$1,148
Pfizer	63	$1,119
Lilly USA, LLC	33	$985
Bristol Myers Squibb	40	$884
Gilead(2 entities)	35	$747
Amgen	24	$594
E.r. Squibb & Sons, L.L.C.	31	$568
GSK	22	$514
Eisai Inc.	21	$453
AbbVie	16	$443
Astellas Pharma US Inc	22	$438
Genentech USA, Inc.	24	$432
Beigene USA, Inc.	15	$378
Incyte Corporation	16	$378
Takeda Pharmaceuticals U.S.A., Inc.	12	$371
Regeneron Healthcare Solutions, Inc.	13	$329
Exelixis Inc.	18	$325
Sanofi	14	$283
EMD Serono, Inc.	14	$273
Pharmaessentia USA Corporation	10	$270
Jazz Pharmaceuticals Inc.	11	$244
Array Biopharma Inc	10	$243
ASD Specialty Healthcare, LLC	5	$240
Fennec Pharmaceuticals, Inc.	9	$219
Cardinal Health 110 LLC	1	$176
AVEO Pharmaceuticals, Inc.	8	$154
Rigel Pharmaceuticals, Inc.	5	$154
Boehringer Ingelheim	7	$147
Sumitomo Pharma America, Inc.	6	$129
Tersera Therapeutics LLC	7	$127
Bayer	6	$123
Stemline Therapeutics Inc.	4	$113
Celltrion USA Inc.	1	$112
Tempus AI, Inc	5	$110
Karyopharm Therapeutics Inc.	6	$106
Myovant Sciences Inc.	5	$95
Pharmacyclics LLC, An Abbvie Company	4	$90
Organon	5	$90
Beone Medicines USA, Inc.	3	$85
Sobi, Inc	4	$84

How this compares

$2,057,651 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$1,310,528

Medicare patients

270

Services billed

77,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Saint Petersburg

Carl LandgrenMiami$47.8M
Julio ChavezTampa$16.4M
Steven AttiaJacksonville$13.9M
Santosh NairOrange City$13.5M
Frederick LockeTampa$12.8M
Tarek MekhailOrlando$11.2M
Carlos AlemanyOrlando$10.9M
Thomas GeorgeGainesville$10.3M
Sikander AilawadhiJacksonville$9.8M
Richard KimTampa$8.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →